drug

AP-101

Phase 2updated 3mo ago

by AL-S Pharma AG

Phase 2

community read0 votes

indications

ALS

all catalysts(0)

nothing on the calendar yet

Trials studying AP-101

phase1Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosiscompletedn=8
phase2A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)completedn=73

News(1)

Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?
Three years after Qalsody was approved by the FDA as the first drug to target a genetic cause of ALS, some patients are reporting not only disease stabilization but also improvement of symptoms.
biospace · 11d ago

Data sources

ClinicalTrials.gov

last refreshed 26m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

AP-101

Phase 2updated 3mo ago

by AL-S Pharma AG

Phase 2

community read0 votes

indications

ALS

all catalysts(0)

nothing on the calendar yet

Trials studying AP-101

News(1)

Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?
Three years after Qalsody was approved by the FDA as the first drug to target a genetic cause of ALS, some patients are reporting not only disease stabilization but also improvement of symptoms.
biospace · 11d ago

Data sources

ClinicalTrials.gov

last refreshed 26m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

AP-101

indications

all catalysts(0)

Trials studying AP-101

News(1)

Report a data issue

comments(0)

AP-101

indications

all catalysts(0)

Trials studying AP-101

News(1)

Report a data issue

comments(0)